Ciclosporin ophthalmic - MC2 Therapeutics

Drug Profile

Ciclosporin ophthalmic - MC2 Therapeutics

Alternative Names: MC2-03; PADciclo 0.03%; PADciclo™; PAD™cyclosporine

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MC2 Biotek
  • Developer MC2 Therapeutics; Moorfields Pharmaceuticals
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 09 Nov 2017 MC2 Therapeutics completes enrolment in its phase II NORTHERN LIGHTS trial for Dry eyes in United Kingdom, Denmark, Austria, Spain, Portugal, Slovakia and Czech Republic (EudraCT2015-000937-54)
  • 03 Aug 2015 Phase-II clinical trials in Dry eyes (Combination therapy) in Czech Republic, Slovakia, Portugal (Ophthalmic) (EudraCT2015-000937-54)
  • 01 Jul 2015 Phase-II clinical trials in Dry eyes (Combination therapy) in Austria and Denmark (Ophthalmic) (EudraCT2015-000937-54)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top